Table 1.
Characteristics of subjects enrolled in serum lipocalin 2 (LCN2) analysis
| Controls | UC | CD | P | |
|---|---|---|---|---|
| Number of subjects (total 223) | 23 | 119 | 81 | |
| Age (range) | 43 (19–71) | 42 (19–76) | 42 (19–71) | n.s. |
| Female sex (%) | 13 (55·6%) | 56 (47·1%) | 35 (43·2) | n.s. |
| Duration of disease(range) | – | 12 (0–40) | 10 (3–28) | n.s. |
| 5-ASA/S-ASA (%) | 0 | 94 (79·0%) | 27 (33·3%) | 0·000α |
| Systemic corticosteroids (%) | 0 | 15 (12·6%) | 24 (29·6%) | 0·007β |
| hsCRP (range) | 1·9 (0·3–12·8) | 2·3 (0·3–96·4) | 4·3 (0·3–67·6) | 0·000γ |
Age, duration of disease and high sensitivity C-reactive protein (hsCRP) are given as median. Gender and medication are given as numbers.
α
Significantly higher use of 5-ASA/salazopyrine in UC versus CD subjects;
β
significantly higher use of systemic steroids in CD versus UC subjects;
γ
significantly higher hsCRP in CD versus both controls and UC subjects. CD: Crohn's disease; UC: ulcerative colitis; n.s.: not significant; 5-ASA/S-ASA: aminosalisylic acid/sulphasalazine.